Key result
Catheter ablation was superior to medical therapy in reducing all-cause mortality and hospitalization, and improving left ventricular ejection fraction and quality of life in patients with atrial fibrillation and heart failure.
Why the study?
AF in the setting of HF accounts for significant mortality, and it can be managed with either rate control or rhythm control strategies.
Does catheter ablation improve clinical outcomes, LVEF, and quality of life in patients with atrial fibrillation and heart failure compared to medical therapy?
Does catheter ablation improve clinical outcomes, LVEF, and quality of life in patients with atrial fibrillation and heart failure compared to medical therapy?
Catheter ablation is superior to medical therapy for managing atrial fibrillation in patients with heart failure, offering significant benefits in mortality, hospitalization, LVEF, and quality of life.
May support ablation in AF with HF; leaves open confirmation in larger randomized trials.
Atrial fibrillation (AF) in the setting of heart failure (HF) accounts for a significant proportion of mortality. AF can be managed either with rate control or rhythm control strategies. Rate control involves the use of beta blockers or calcium channel blockers. Rhythm control methods use antiarrhythmic drugs or catheter ablation (CA) to abolish the rhythm. Articles from PubMed and Google Scholar were chosen for review. The literature was reviewed for data from the last 10 years to be chosen for interpretation. Clinical trials, meta-analyses, and systematic analysis were included in this study. Various health parameters such as all-cause mortality, hospitalization rates, sinus rhythm (SR) maintenance, quality of life improvement, stroke risk, left ventricular ejection fraction (LVEF) improvement, and healthcare costs were analyzed. We demonstrated that CA was superior to medical therapy in reducing all-cause mortality and hospitalization. It leads to significant improvement in LVEF as SR was maintained consistently. Overall, quality of life improved in those who underwent ablation as compared to those who did not. Stroke risk reduction was seen in observational studies only. We recommend CA as first-line therapy for treating patients with AF in the setting of HF. More clinical trials are needed to determine the effectiveness of ablation in reducing stroke risk.
No takes yet. Share an insight, caveat, or question.
Oble et al. (2023) conducted a review in Atrial fibrillation and heart failure. Catheter ablation vs. Medical therapy was evaluated on All-cause mortality, hospitalization rates, LVEF, QoL, stroke risk, and cost of treatment (p=<0.05). Catheter ablation was superior to medical therapy in reducing all-cause mortality and hospitalization, and improving left ventricular ejection fraction and quality of life in patients with atrial fibrillation and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: